J. Gilles

发表

A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII Concentrate

J. Vermylen, J. Arnout, J. Vermylen, 1993, Thrombosis and Haemostasis.

Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate

J. Arnout, J. Vermylen, K. Peerlinck, 1997, Thrombosis and Haemostasis.

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A novel cause of mild/moderate hemophilia A: mutations scattered in the factor

J. Vermylen, M. Hoylaerts, T. VandenDriessche, 2022 .

Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.

J. Vermylen, M. Hoylaerts, J. Arnout, 1999, Blood.

Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies.

J. Saint-Remy, J. Gilles, 1994, The Journal of clinical investigation.

Latex allergosorbent test (LAST): a new immunoassay for specific IgE with latex particles.

J. Saint-Remy, J. Gilles, J. Mareschal, 1988, The Journal of allergy and clinical immunology.

Humanized severe combined immunodeficient mice as a potential model for the study of tolerance to factor VIII.

J. Vermylen, J. Saint-Remy, J. Gilles, 2000, Thrombosis and haemostasis.

Seasonal variation in specific IgE antibodies of grass-pollen hypersensitive patients depends on the steady state IgE concentration and is not related to clinical symptoms.

J. Saint-Remy, J. Gilles, J. Machiels, 1989, The Journal of allergy and clinical immunology.

Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor

C. Granier, J. Saint-Remy, J. Gilles, 2003, Thrombosis and Haemostasis.

Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.

J. Arnout, J. Vermylen, J. Saint-Remy, 1993, Blood.

A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.

L. Vander Elst, K. Thielemans, R. Schwaab, 2000, Blood.

Some Factor VIII (FVIII) Inhibitors Recognise a FVIII Epitope(s) that Is Present only on FVIII-vWF Complexes

J. Vermylen, M. Hoylaerts, J. Vermylen, 1999, Thrombosis and Haemostasis.

Point mutations scattered in the FVIII C1 and C2 domains reduce FVIII binding to vWF and are associated to mild/moderate hemophilia A

R. Schwaab, J. Vermylen, K. Peerlinck, 1999 .

Natural Autoantibodies and Anti-Idiotypes

J. Saint-Remy, J. Gilles, B. Vanzieleghem, 2000 .

Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.

M F Hoylaerts, J. Vermylen, L. Vander Elst, 1998, Blood.

Coagulation Factor VIII Autoantibodies

J. Saint-Remy, J. Gilles, 1996 .

In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody.

M. de Maeyer, J. Saint-Remy, J. Gilles, 2004, Blood.

Factor VIII Inhibitors

J. Saint-Remy, J. Gilles, M. Jacquemin, 1997, Thrombosis and Haemostasis.

Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A.

J. Vermylen, J. Saint-Remy, H. Lenk, 1996, The Journal of clinical investigation.

Restricted epitope specificity of anti-FVIII antibodies that appeared during a recent outbreak of inhibitors.

J. Arnout, J. Vermylen, K. Peerlinck, 1997, Thrombosis and haemostasis.

Coagulation Factor autoantibodies

J. Saint-Remy, J. Gilles, 2007 .

Factor VIII Inhibitors. Natural autoantibodies and anti-idiotypes.

J. Saint-Remy, J. Gilles, B. Vanzieleghem, 2000, Seminars in thrombosis and hemostasis.

Role of anti‐idiotypic antibodies in immune tolerance induction

J. Gilles, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

Deletion of residue Ala2201 in the Factor VIII C2 domain results in mild haemophilia A and destroys a major antigenic determinant recognized by Factor VIII inhibitor antibodies

B. Stoddard, J. Vermylen, K. Peerlinck, 2001 .

cofactor activity and binding to von Willebrand factor A human antibody directed to the factor VIII C1 domain inhibits factor VIII

J. Vermylen, K. Thielemans, R. Schwaab, 2013 .

A patient with mild hemophilia A and a high titer antifactor VIII antibody against exogenous factor VIII only: clinical features, surgical management, and partial characterization of the inhibitor

J. Vermylen, K. Peerlinck, J. Saint-Remy, 1997 .

Variations in Antigenicity of Factor VIII Concentrates: Preclinical Evaluation

J. Saint-Remy, J. Gilles, 1996, Vox sanguinis.

In vivo production of functional anti-factor VIII antibodies in severe combined immunodeficiency (SCID) mice reconstituted with PBL of healthy blood donors

J. Vermylen, J. Saint-Remy, J. Gilles, 1997 .

Heating Lyophilised Factor VIII Does Not Alter Its Recognition by Specific Antibodies

J. Saint-Remy, J. Gilles, R. Laub, 1997, Vox Sanguinis.